Multiple sclerosis–associated CD226 variant disrupts vitamin D–induced type I Treg differentiation by impairing LFA-1 activation
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci202193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Saniya Kari und 18 weiteren Autor:innen. Beteiligte Einrichtung: Univ Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France. Hauptthemen laut MEDLINE: Multiple Sclerosis, T-Lymphocytes, Regulatory, Cell Differentiation, Antigens, Differentiation, T-Lymphocyte. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Foundation France SEP, Centre National de la Recherche Scientifique.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a complex inflammatory disease of the CNS resulting from an intricate interplay between genetic predisposition and environmental factors. Vitamin D (VD) deficiency is one of the established risk factors for MS. CD46 costimulation of CD4 + T cells induces a switch from Th1 to type I regulatory cells (Tr1), characterized by increased IL-10 production. This switch is impaired in MS T cells but can be restored by VD, which also strongly promotes expression of CD226 on CD46-activated T cells. The rs763361 polymorphism in the CD226 gene, resulting in a nonsynonymous Gly307Ser variant, is associated with increased risk for MS. Herein, we show that expression of this CD226 risk allele disrupts the ability of CD46-activated T cells to operate the IFN-γ/IL-10 switch upon VD exposure. Mechanistically, the risk variant impairs activation of the integrin LFA-1, which promotes the Tr1 phenotype. LFA-1–mediated Tr1 differentiation is also impaired in MS T cells expressing the CD226 risk allele upon CD46 and VD stimulation. Our study unveils how, in the context of MS susceptibility, a genetic polymorphism and an environmental factor act in concert to control the differentiation of Tr1 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France.
- School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands.
- MS Center ErasMS, Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam, Netherlands.
- Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands.
- Medical University of Vienna, Department of Dermatology, Vienna, Austria.
Förderung
- Agence Nationale de la Recherche
- Foundation France SEP
- Centre National de la Recherche Scientifique
- ANR
Zitieren
APA
Kari, S., Debonlier, A., Angles, T., Chaves, B., Grosjean, C., Bucciarelli, F., Duplan-Eche, V., Nozeran, L., Lavery, J., Morandi, E., Pignolet, B., Mimpen, M., Smolders, J., Liblau, R., Saoudi, A., Damoiseaux, J., Masson, F., Dupré, L., & Astier, A. L. (2026). Multiple sclerosis–associated CD226 variant disrupts vitamin D–induced type I Treg differentiation by impairing LFA-1 activation. Journal of Clinical Investigation. https://doi.org/10.1172/jci202193
Vancouver
Kari S, Debonlier A, Angles T, Chaves B, Grosjean C, Bucciarelli F, et al. Multiple sclerosis–associated CD226 variant disrupts vitamin D–induced type I Treg differentiation by impairing LFA-1 activation. Journal of Clinical Investigation. 2026. doi:10.1172/jci202193
BibTeX
@article{Kari2026,
author = {Kari, Saniya and Debonlier, Aymeline and Angles, Thibault and Chaves, Beatriz and Grosjean, Charles and Bucciarelli, Florence and Duplan-Eche, Valérie and Nozeran, Lucie and Lavery, Jessica and Morandi, Elena and Pignolet, Beatrice and Mimpen, Max and Smolders, Joost and Liblau, Roland and Saoudi, Abdelhadi and Damoiseaux, Jan and Masson, Frederick and Dupré, Loïc and Astier, Anne L},
title = {Multiple sclerosis–associated CD226 variant disrupts vitamin D–induced type I Treg differentiation by impairing LFA-1 activation},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci202193}
}
EUVIMED